Celsion's heat-reactive liposomes in liver cancer tests
This article was originally published in Clinica
The US National Institutes of Health (NIH) is to test whether targeted delivery of a cancer-killing drug using Celsion's temperature-sensitive liposomes can improve the treatment of liver cancer.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.